Matt Feldman, MD

Closing out their discussion on the management of atopic dermatitis, expert panelists share clinical pearls and key takeaways from their discussion.

Shared insight on the best ways to educate patients on their atopic dermatitis and explain the nuances of available therapies.

A broad look at the ongoing challenges and unmet needs in the field of atopic dermatitis management.

Marc Serota, MD, elucidates the heterogeneity of atopic dermatitis and explains how this can contribute to challenges in treating patients.

Expert panelists share excitement for novel therapies in the pipeline for the management of atopic dermatitis.

Taking into account all available topical and systemic therapies, Marc Serota, MD, provides his optimal sequencing strategy for patients with atopic dermatitis.

Drs. Lio, Feldman and Jain reflect on the adverse event profile of JAK inhibitor therapy in atopic dermatitis and consider when these agents are appropriate for use.

An overview of the three JAK inhibitor therapies available for the management of atopic dermatitis.

Expert perspectives on the interleukin pathway inhibitors, dupilumab and tralokinumab, and their role in managing atopic dermatitis.

A brief discussion on how the coronavirus 2019 pandemic has impacted the management of patients with atopic dermatitis.

Considerations for managing mild-to-moderate versus moderate-to-severe atopic dermatitis and which therapies are appropriate in each setting.

Shared insight on the systemic treatment armamentarium for atopic dermatitis and how it has evolved in recent years.

Moving on to discuss treatment options for patients with atopic dermatitis, experts reflect on optimal use of topical agents in this setting.

A panel of experts discuss role of guidelines and importance of shared-decision making in managing patients with atopic dermatitis.

Expert perspectives on assessing quality of life when discussing atopic dermatitis and inflammatory disease with patients.

Shared insight on the nature of inflammation in conjunction with atopic dermatitis with special considerations for possible contributors and severity of disease.